Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.
Saved in:
| Title: | Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. |
|---|---|
| Authors: | Omange WR; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Varco-Merth BD; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Fadeyi O; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Marenco A; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Takata H; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Duell DM; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Goodwin WD; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Armitage P; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Fennessey CM; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Kose E; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Immonen TT; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Kosmider E; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Bosche WJ; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Fast R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Homick C; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Oswald K; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Shoemaker R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Bochart R; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., MacAllister R; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Labriola CS; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Smedley JV; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Axthelm MK; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Edlefsen PT; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Lifson JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Gergen J; CureVac SE, Tübingen, Germany., Petsch B; CureVac SE, Tübingen, Germany., Rauch S; CureVac SE, Tübingen, Germany., Picker LJ; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Okoye AA; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA. |
| Source: | The Journal of clinical investigation [J Clin Invest] 2026 Jan 29; Vol. 136 (6). Date of Electronic Publication: 2026 Jan 29 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
